Omnicell Names Veteran Surgical Robotics Exec as Its New CTO

Perry Genova most recently served as SVP of R&D at EndoQuest Robotics and Titan Medical USA. He has more than 25 years of experience in product development, strategic planning, and regulatory compliance.

Perry A. Genova is joining Fort Worth-based Omnicell as senior vice president, chief technology officer, effective March 31.

“We believe Perry’s entrepreneurial mindset will be pivotal to advancing our multi-year, outcome-centric growth strategy as we strive to deliver clinical and operational outcomes for our customers,” Nnamdi Njoku, EVP and COO at Omnicell, said in a statement. “His focus on building trust and collaboration among strategic partners and internal and external stakeholders will help to drive forward our purpose to transform medication management across all care settings.”

Since 1992, Omnicell said it has been committed to transforming pharmacy and nursing care via outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care.

In his new role, Genova will lead Omnicell’s technology strategy as it works to address pressing issues within medication and supply management across all care settings in an effort to help customers move closer to the industry-defined vision of the Autonomous Pharmacy.

Genova has more than 25 years of experience in product development, strategic planning, and regulatory compliance, and the company said he has a track-record of success in delivering innovation, growth, and value in senior leadership roles for companies across the medical device, pharmaceutical, and life sciences industries

Genova focused on delivering innovation, growth, and value as SVP of research and development at EndoQuest Robotics Inc. and Titan Medical USA, President and CEO at Centauri Robotic Surgical Systems Inc. and Oncoscope Inc., and vice president at GSK plc (formerly GlaxoSmithKline plc) and Kos Pharmaceuticals Inc.

Among Genova’s achievements are building an $800 million division at Kos Pharmaceuticals Inc., helping develop a class-leading reservoir insulin device, and holding 58 issued U.S. patents spanning a spectrum of medical and consumer technologies.


Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.

One quick signup, and you’re done.

 

R E A D   N E X T

Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.